Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Proteoglycans in the liver].

Ilona Kovalszky1, József Dudás, Mónika Gallai

  • 1I. sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest 1085, Hungary. koval@korb1.sote.hu

Magyar Onkologia
|November 3, 2004
PubMed
Summary

Proteoglycans, like syndecan-1, change in liver disease and cancer, impacting cell behavior and potentially driving malignancy. Altered heparan sulfate chains in liver cancer reduce biological activity and inhibit key enzymes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights.

International journal of molecular sciences·2026
Same author

Photodynamic therapy in head and neck squamous cell carcinoma: immunomodulation and stromal targeting of cancer-associated fibroblasts.

Translational oncology·2026
Same author

Granzyme B, HIF-1α, VEGFA and SerpinB9 in the local tumour immune system of immune-stimulated slice cultures of head and neck cancer.

BMC cancer·2026
Same author

Immunomodulatory effects of short-chain fatty acids and immune-supporting nutrients on slice cultures of head and neck tumors.

Frontiers in nutrition·2026
Same author

Ginger and Its Purified Major Components Inhibit Clinically Relevant Uptake and Efflux Transporters In Vitro.

Pharmaceutics·2026
Same author

Editorial: Cytometry in oncology.

Pathology oncology research : POR·2026

Area of Science:

  • Biochemistry and Molecular Biology
  • Cell Biology
  • Oncology

Context:

  • Proteoglycans, macromolecules with protein cores and sugar chains, are vital on cell surfaces and in the extracellular matrix (ECM).
  • Syndecan-1 is the primary transmembrane proteoglycan in normal liver, with ECM proteoglycans in stromal components.
  • Alterations in proteoglycan levels and localization are observed in liver cirrhosis and hepatocellular carcinoma.

Purpose:

  • To investigate the role and structural changes of proteoglycans, specifically syndecan-1, in the context of liver cirrhosis and cancer.
  • To understand how modifications in proteoglycans, particularly heparan sulfate chains, affect biological activity and cellular regulation in liver cancer.

Summary:

  • In liver cirrhosis, proteoglycan levels increase. Liver cancer exhibits abnormal syndecan-1 localization and agrin-rich stroma.

Related Experiment Videos

  • Heparan sulfate chains in liver cancer are undersulfated, leading to reduced binding of transcription factors and loss of topoisomerase I inhibition.
  • A truncated form of syndecan-1 promotes hepatoma cell differentiation and inhibits syndecan-1 shedding, highlighting its regulatory significance.

    • Impact:

    • Structural alterations in proteoglycans are implicated in the development of the malignant phenotype in liver cancer.
    • Undersulfated heparan sulfate chains in liver cancer compromise essential biological functions.
    • Syndecan-1 shedding emerges as a critical regulatory mechanism influencing cell behavior in hepatoma.